Immediately discontinue use in presence of suspected or apparent significant hepatic dysfunction. Risk of developing hepatic failure &/or clotting abnormalities. Patients w/ prior history of hepatic disease; on multiple anticonvulsants, those w/ congenital metabolic disorders, severe seizure disorders accompanied by mental retardation, & organic brain disease. Do not abruptly discontinue use. Perform LFTs prior to therapy & at frequent intervals thereafter, especially during the 1st 6 mth. Increased risk of congenital malformations w/ maternal use during pregnancy. Use w/ extreme caution & as sole agent in childn <2 yr.
Sign Out
